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Approximately 30-40% of patients with well-differentiated neuroendocrine tumors present with carcinoid
syndrome, which is a paraneoplastic syndrome associated with the secretion of several humoral factors.
Carcinoid syndrome significantly and negatively affects patients’ quality of life; increases costs compared with
the costs of nonfunctioning neuroendocrine tumors; and results in changes in patients’ lifestyle, such as diet,
work, physical activity and social life. For several decades, patients with neuroendocrine tumors and carcinoid
syndrome have been treated with somatostatin analogues as the first-line treatment. While these agents
provide significant relief from carcinoid syndrome symptoms, there is inevitable clinical progression, and new
therapeutic interventions are needed. More than 40 substances have been identified as being potentially
related to carcinoid syndrome; however, their individual contributions in triggering different carcinoid
symptoms or complications, such as carcinoid heart disease, remain unclear. These substances include serotonin
(5-HT), which appears to be the primary marker associated with the syndrome, as well as histamine, kallikrein,
prostaglandins, and tachykinins.
Given the complexity involving the origin, diagnosis and management of patients with carcinoid syndrome,
we have undertaken a comprehensive review to update information about the pathophysiology, diagnostic
tools and treatment sequence of this syndrome, which currently comprises a multidisciplinary approach.
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’ INTRODUCTION
Carcinoid syndrome (CS) is a paraneoplastic syndrome
associated with the secretion of several humoral factors, such
as polypeptides, vasoactive amines, and prostaglandins (1).
The main symptoms of CS are episodic facial flushing that
may be accompanied by hypotension and tachycardia, diarrhea,
bronchoconstriction, venous telangiectasia, dyspnea and ulti-
mately fibrotic complications such as mesenteric and retro-
peritoneal fibroses and carcinoid heart disease (CHD) (2).
CS is predominantly associated with neuroendocrine tumors
(NETs) that arise from the midgut in the setting of extensive
liver metastases but may be present in patients with bron-
chial carcinoids and, more rarely, in patients with pancreatic
NETs. In patients with extensive liver metastases, a large amount
of tumor-secreted substances are not completely metabolized
by hepatic or pulmonary cells and enter the systemic cir-
culation, causing carcinoid symptoms; carcinoid-produced
substances may also enter the systemic circulation when
the patient exhibits forame ovale or when the primary tumor
is located in the bronchi (2).
Considering all types of NETs and all stages, among
patients 65 years old or older, a large epidemiological study
from the US reported that 19% of this patient population
had CS (3). This study evaluated 9,512 patients with a
diagnosis of NET and concluded that CS has a significant
association with tumor grade, more advanced stage and
midgut primary site, as well as a significant reduction in
the overall survival of affected patients. CS also significantly
and negatively affects patients’ quality of life (4); increases
costs compared with the costs of nonfunctioning NETs; and
results in changes in the patients’ lifestyle, such as diet, work,
physical activity and social life (5). A cross-sectional study
conducted in twelve countries with 1,928 patients with NETs
has shown that 49% of patients miss work due to their disease
(6). Among the patients who did not work, the vast majority
(82%) left their work because of the illness, demonstrating the
strong negative impact of NETs on patients’ lives.
For several decades, patients with NETs and CS have been
first treated with somatostatin analogues. While these agents
provide significant relief from CS symptoms, there is inevi-
table clinical progression, when new therapeutic interven-
tions are needed. Given the complexity involving the origin,
diagnosis and management of patients with CS, we have
undertaken a comprehensive review to update our knowledge
about the pathophysiology, diagnostic tools and treatment
options for this syndrome.DOI: 10.6061/clinics/2018/e490s
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Pathophysiology
More than 40 substances have been identified as being
potentially related to CS; however, their individual contribu-
tions in triggering different carcinoid symptoms and compli-
cations, such as CHD, remain unclear (7). These substances
include serotonin (5-HT), which appears to be the primary
marker associated with the syndrome, as well as histamine,
kallikrein, prostaglandins, and tachykinins (2). Below, we
discuss the characteristics of the most common carcinoid
symptoms and their related complications, which are sum-
marized in Table 1 and Figure 1.
Flushing
Flushing is a subjective sensation of warmth that is accom-
panied by reddening of the skin anywhere on the body,
especially the face, neck, and upper torso (8). In over 90%
of cases, flushing is the clinical hallmark of functional NETs
and is often episodic (9). Vasoactive substances, usually
secreted by functioning NETs that are located distal to the
portal vein or downstream of functioning hepatocytes,
such as 5-HT, substance P, histamine, catecholamines, and
prostaglandins, provoke flushing when they are not inacti-
vated by hepatocytes (10,11). The release of carcinoid-related
substances is usually triggered by amine-rich foods (chocolate,
banana, kiwi, avocado and nuts), alcohol and an increase in
adrenergic activities, such as physical exercise. Importantly,
a recent retrospective study demonstrated that the use of
serotoninergic antidepressants was safe to treat depressive
symptoms and did not significantly worsen carcinoid
symptoms (12).
Figure 1 - Summary of the pathophysiology of carcinoid syndrome.
Table 1 - Symptoms and signs of carcinoid syndrome.
Symptom Frequency % Characteristics Involved mediators
Flushing 90 (9) Foregut: long-lasting, purple (9-11) Catecholamines, 5-HT, histamine,
substance P (10,11)
Midgut: short-lasting, pink to red color, face and trunk,
can occur several times a day for a few minutes (9-11)
Catecholamines, histamine, substance P,
prostaglandins (10,11)
Diarrhea 60-80 (14) Secretory: intermittent accompanied by
abdominal cramping (14,15)
Gastrin, 5-HT, histamine, prostaglandins,
VIP (16,19)
Abdominal pain 35 Progressive (54) Small bowel obstruction, hepatomegaly,
ischemia (2)
Bronchospasm 15 (20) Wheezing (20) Histamine, 5-HT (20)
Pellagra 5 (31) Dermatitis, diarrhea, dementia (31) Niacin deficiency
CHD 19-60 (32,33) Dyspnea, holosystolic murmur radiating to
the right side of the chest (32)
5-HT, bradykinins, tachykinins, activin A,
tissue growth factor (32)
Mesenteric Fibrosis 50 (53) Ischemia of vessels: decreased absorption of nutrients,
ascites, intestinal obstruction, ureteral obstruction (54)
5-HT, TGF-beta (53,58)
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While 5-HT is the proposed main causative agent of
CS-associated flushing, as evidenced by elevated levels of
a known 5-HT metabolite, 5-hydroxyindoleacetic acid (5-
HIAA), in the 24-h urine test, there is some speculation that
other peptides are involved because some characteristics of
flushing differ across patients. For example, a rapid cyanotic
facial and trunk flush with a mild burning sensation that
lasts less than a minute is commonly associated with midgut
NETs; on the other hand, foregut tumors tend to produce
pruritic wheals that are reddish-brown and occur over the
entire body (9). Moreover, some NET patients present flush-
ing with low or normal levels of 5-HIAA, while patients
who have high levels of urinary 5-HIAA are totally asymp-
tomatic (13).
Diarrhea
The prevalence of CS-associated diarrhea among NET
patients with elevated urinary 5-HIAA is as high as 60-80%
(14). However, this type of diarrhea is not typical but rather
unspecific, usually described as intermittent and sporadic
and often accompanied by mild abdominal cramping, and it
may become continuous when complicated by bacterial
overgrowth (14,15). This somewhat atypical course may
explain the delayed diagnosis of NETs (14), which can
sometimes be after many years of uncomplicated and mild
symptoms that result in many patients being diagnosed with
advanced incurable disease. Because 5-HT acts physiologi-
cally by stimulating intestinal motility and intestinal secre-
tion, high levels of 5-HT could induce increased frequency
of bowel movements and decrease stool consistency; this
is observed clinically as patients with CS diarrhea and is
described as secretory. For example, a preclinical study (16)
using human intestinal mucosa that was resected during
surgery for Crohn’s disease showed that 5-HT induces secre-
tion across the human ileal mucosa via the 5-HT4 subtype
receptors, whereas the 5-HT2A receptor appears to mediate
the gut effects of 5-HT in the human sigmoid colon (16). The
most recent evidence that CS is caused by elevated 5-HT is
the significant reduction in the frequency of daily bowel
movements and urinary 5-HIAA levels demonstrated in the
phase III placebo-controlled trial of telotristat ethyl, an oral
inhibitor of 5-HT synthesis (17). Nevertheless, other sub-
stances may be cosecreted with 5-HT, causing diarrhea (18).
For example, other physiological factors normally secreted
by endocrine gut cells, such as histamine, kallikrein and
substance P, could, if overproduced, lead to diarrhea (19).
Methods to properly measure the serum levels of these
substances are needed.
Bronchospasm
There are very few studies on CS-associated bronchospasm.
In a retrospective study with 748 CS patients, the prevalence of
bronchospasm was 15% (20). The underlying mechanism is
not clear. Patients who complain about bronchospasm tend to
report concurrent flushing, sneezing and dyspnea. Secretion of
histamine and 5-HT by the tumor are probably linked to the
mechanisms of bronchospasm.
Carcinoid crisis
A carcinoid crisis is a serious and potentially life-
threatening exacerbation of CS due to the release of large
amounts of amines in the circulation. Carcinoid crisis is
characterized by hypotension, arrhythmias, tachycardia,
flushing and bronchospasm, and it can be lethal. Carcinoid
crisis can occur spontaneously, but it is more common after
stressful procedures such as anesthesia, surgery or radiologic
interventions. While prophylactic use of short-acting soma-
tostatin analogues has been suggested and widely used to
prevent carcinoid crisis that could be induced by invasive
procedures, some patients still experience uncontrolled carci-
noid symptoms (2,21). Recently, Massimino et al. (22) repor-
ted that a 500-mg bolus of octreotide acetate administered
preoperatively was insufficient to prevent intraoperative
carcinoid crisis. In contrast, Woltering et al. (23) observed that
only 3.4% of CS patients experienced intraoperative crisis
using continuous infusion of IV octreotide acetate preopera-
tively. Given the life-threatening consequences of carcinoid
crisis, we recommend that prophylactic and intraoperative
octreotide be administered to all patients with CS and/or
elevated urinary 5-HIAA levels when they are treated with
invasive interventions such as hepatic embolization and
liver biopsy as well as during surgical procedures (24).
’ SYMPTOMS ASSOCIATED WITH TRYPTOPHAN
OR NIACIN DEPLETION
In a normal context, 99% of tryptophan is used in the
synthesis of nicotinic acid, while the remaining is utilized to
produce 5-HT. Tryptophan is catabolically degraded by two
competing pathways that produce either 5-HT or beta-
nicotinamide adenine dinucleotide (NAD), which is an active
form of niacin (vitamin B3). Since tumors associated with CS
can consume up to 60% of tryptophan in the human body
(25), if not properly treated, patients may experience adverse
events resulting from tryptophan and/or niacin deficiencies.
Such a state of deprivation may cause several problems,
including pellagra and neurocognitive disturbances, as
discussed below.
Neuropsychological symptoms
It has been estimated that extreme tryptophan deprivation
can lead to an 87% to 97% reduction in the levels of 5-HT
synthesized in the brain (26). Russo et al. (27) demonstrated
lower tryptophan serum levels in CS patients. Pasieka et al.
(28) compared 36 CS patients with 20 healthy controls
through self-report cognitive questionnaires and a battery of
six standardized neurocognitive tests. They demonstrated
that patients with CS presented greater cognitive dysfunction
than healthy controls. Supporting the concept that CS indu-
ces neurocognitive dysfunction through tryptophan deple-
tion, studies with drugs that inhibit 5-HT synthesis have
reported associated depressive symptoms. In 1967, Engel-
man et al. (29) tested para-chlorophenylalanine, a drug that
inhibits tryptophan hydroxylase (TPH), which is the enzyme
involved in 5-HT synthesis, in patients with CS. While the
investigators observed reduced levels of 5-HIAA and CS
symptom improvement, they described severe neurological
adverse effects, including major depression, and the clinical
development of this drug was halted. Recently, in the phase
III placebo-controlled trial TELESTAR (30) with telotristat
ethyl, patients who received 500 mg of telotristat three times
per day (TID) reported more depressive symptoms (15.6%
of patients taking telotristat versus 6.7% of patients taking the
placebo) than those who were treated with 250 mg TID or
placebo. Longer duration of treatment with telotristat ethyl and
more studies with a larger number of patients are necessary to
properly evaluate the neurological effects of this drug.
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However, it is not possible to infer direct and exclusive
causality between tryptophan depletion and neurological
impairment given that the cancer itself may lead to emo-
tional stress that could affect cognition; other tumor-secreted
substances and malnourishment resulting from uncontrolled
diarrhea could also contribute to neurological/cognitive dys-
function. Longitudinal studies with control groups of healthy
and nonfunctioning NET patients could better evaluate
whether and to what extent neurocognitive dysfunction
occurs in patients with CS.
Pellagra
Pellagra is a clinical condition caused by niacin deficiency
(vitamin B3) characterized by dermatitis, diarrhea and
dementia in severe cases. The actual prevalence of pellagra in
patients with CS is unknown, although some studies have
reported that approximately 5% of CS patients experience
pellagra (31). Fortunately, pellagra is rarely seen after the
incorporation of somatostatin analogues into the therapeutic
arsenal for NET treatment. However, in developing coun-
tries, somatostatin analogues are not available in the public
systems, such as in the public health system of Brazil. In such
settings, it is not uncommon to see CS patients presenting
with long-term uncontrolled symptoms, including intense
skin pruritus resulting from pellagra. Figure 2 demonstrates
a patient with pellagra and niacin deficiency due to long-
term CS that was not adequately controlled due to lack of
adherence to somatostatin analogues.
’ SYMPTOMS ASSOCIATED WITH FIBROTIC
COMPLICATIONS
Carcinoid heart disease
CHD is part of the CS spectrum and is associated with
high mortality and morbidity (2). Its incidence varies, rang-
ing from 19% to 60% (1), depending on the patient popu-
lation, access to somatostatin analogues, definition of CHD
and methods used for diagnosis (1,2). CHD is characterized
by deposition of fibrous tissues on the valves primarily
affecting the right heart chambers, particularly the tricuspid
valve, because circulating 5-HT is inactivated in the lungs
(32). Therefore, left valve involvement is rare and is usually
associated with a higher risk of interatrial shunt that may be
present in these patients due to overload of the right atrium.
The exact mechanism underlying the development of CHD
remains unclear. However, there is strong evidence for the role
of 5-HT in the fibrogenesis and stimulation of fibroblast
growth in CHD (2). Several studies have shown that urinary
levels of 5-HIAA were significantly higher in patients with
CHD than in those without this condition (1,33). There are
seven classes of 5-HT receptors, and 5-HT2B is the receptor in
the cardiovascular system that may be involved in fibrogen-
esis (34). The following evidence points to an important role
of 5-HT in the development of CHD: serotonergic drugs
(fenfluramine, pergolide, cabergoline, and ergotamine by-
products) have been shown to cause valve fibrosis similar to
that observed with CHD (35); in vitro studies have shown the
mitogenic action of 5-HT in fibroblasts, smooth muscle cells,
and endothelial cells (36,37); studies with animals exposed to
high levels of IV 5-HT showed that they developed cardiac
valve dysfunction (38-40); and lastly, it has been demon-
strated in animal models that hyperexpression of 5-HT2B
receptors in the heart leads to cardiac hypertrophy because
of increased deposition and remodeling of the extracellular
matrix (41), whereas deletion of 5-HT2B leads to ventricular
dilation and incomplete development of the heart (42).
Therefore, activation of the 5-HT2B receptor triggers distinct
intracellular signaling pathways, which in turn may result in
a stronger inflammatory response and release of cytokines
including TNF-alpha (43), activation of the MAPK (44) signa-
ling pathway and hyperexpression of TGF-beta (45), all
converging to cardiac fibrosis.
Despite the strong evidence of 5-HT involvement in the
development of CHD, a significant proportion of patients
with elevated plasma levels of 5-HT do not develop this
condition (46), which suggests that there are other biochem-
ical or genetic mechanisms involved. For example, other
potential contributing factors are bradykinins, tachykinins,
activin A and tissue growth factor (CTGF). Bradykinins (46)
are associated with endocardium injury that results in
fibrosis as a response mechanism of the endocardium (46). In
addition, tachykinins have been described as endocardial
fibroblast pro-proliferative agents that induce plaque forma-
tion. Activin A is a cytokine and a member of the TGF-beta
superfamily with fibrogenic properties, and its expression
has been demonstrated in fibrotic plaques of patients with
CHD (47). Hyperexpression of CTGF and TGF-beta1 mRNA
in intestinal NETs, which together promote the overproduc-
tion of collagen and fibrosis, has been described by Kidd
et al. (48,49); the overexpression of TGF-beta1 (50) is also
stimulated by 5-HT2B receptors, mostly found in the heart.
Beyond tumor-related risk factors for CHD, clinical fea-
tures may be associated with the onset of CHD among
Figure 2 - Patient with pellagra, in whom we observed dry skin
and scratches from intense itching.
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CS patients. In a case-control study of 42 NET patients with
or without CHD but all with elevated urinary 5-HIAA levels
that was conducted by our group, we found that 38% (95%
confidence interval: 23 to 54%) presented with CHD, defined
as at least moderate tricuspid valve regurgitation (51). In our
study, a concurrent or prior diagnosis of cardiovascular
comorbidities was associated with CHD [odds ratio 6.58
(1.09; 39.78), p=0.040]. Patients with cardiovascular dis-
eases often present endothelial dysfunction, marked by
chronic endothelial inflammation and abnormalities in
platelet aggregation function, and it is possible that CHD
patients have a higher concentration of 5-HT in platelets in
the heart, leading to cardiac fibrosis through activation of
5-HT2B receptors (52).
While the initial disease of CHD is usually asymptomatic,
symptoms of right heart failure, such as peripheral edema,
abdominal discomfort and indigestion, early satiety and
cachexia, appear during the course of its evolution. As the
condition worsens, fatigue, dyspnea upon exertion, jugular
swelling, and ascites are observed. If these symptoms are not
treated, progression of the manifestations leads to death from
heart failure.
Mesenteric fibrosis
Mesenteric fibrosis (MF) is another complication of uncon-
trolled CS. At least some signs of MF occur in approximately
50% of CS patients (53), g consequent to a fibrotic and desmo-
plastic reaction around metastatic mesenteric lymph nodes.
MF is a pathognomonic radiological sign of midgut NET,
which can be observed on computerized tomography and
nuclear magnetic resonance images (54-56). MF is usually
detected radiologically and may have the appearance of a
mesenteric mass with the opacity of soft tissue radiating
outward in a ‘‘wheel spoke’’ appearance (53). MF can lead to
ischemia of vessels and intestinal obstruction. This vascular
ischemia can lead to bowel congestion and result in decreased
absorption of nutrients and can also cause ascites and
more severe cases of mesenteric ischemia. Another rare
complication of MF is ureteral obstruction, which may
cause renal failure (54).
5-HT secreted by NETs appears to play a central role in MF.
A recent study demonstrated a significant association of MF
with elevated urinary 5-HIAA levels, suggesting a potential
causal relationship (54). Another study with 52 patients with
midgut NETs demonstrated that elevated platelet 5-HT is
associated with the presence of a mesenteric mass (57).
Another substance that may be involved in pathophysiol-
ogy of MF is TGF-beta, which may play a critical role in
fibrogenesis due to its known ability to stimulate collagen
synthesis (58).
Diagnosis
The diagnosis of CS requires the combination of carcinoid
symptoms and evidence of elevated levels of 5-HIAA in a
24-h urine sample. The sensitivity and specificity of this test
for CS are higher than 90% in patients with characteristic
symptoms (59). However, clinicians should be aware of false
positive findings that could be due to the use of serotoni-
nergic drugs (antidepressants, tramadol, acetaminophen, sali-
cylates, L-DOPA) and patients’ consumption of foods rich in
5-HT. Therefore, to increase the accuracy of the diagnosis, it is
advisable to avoid using serotonergic drugs and avoid foods
such as banana, kiwi, avocado, pineapple, nuts, coffee, etc., for
2 days before and during the 24-h urine collection.
The diagnosis of CHD is performed by transthoracic echo-
cardiography, which shows valve thickening with retrac-
tion and reduction in the mobility of the tricuspid valve in
patients with CS (2,24). Nuclear magnetic resonance imaging
of the heart also allows analysis of ventricular anatomy
and function, thereby contributing to a better assessment
of valvular changes when the echocardiogram is not con-
clusive (32). NT-proBNP, a marker of heart failure, is a useful
serum biomarker in the screening of heart disease in patients
with CS.
MF is diagnosed with an abdominal imaging exam
(usually tomography or NMR) that shows at least a spicula-
ted mass with attenuation in the soft tissue range, with
fibrotic bands that radiate outward from the mesenteric fat
tissue with a star pattern around a metastatic lymph node
(56). Figure 3 shows a typical case of MF secondary to CS
from midgut NET.
Treatment
The main pillar of treatment for CS is the use of soma-
tostatin analogues, such as octreotide and lanreotide. Approxi-
mately 80% of well-differentiated tumors express somatostatin
receptors in the NET cell surface (60). Octreotide and
lanreotide bind to somatostatin receptors and inhibit the
secretion of several hormones and vasoactive substances,
thus improving flushing and diarrhea symptoms in over 80%
patients with CS (61). Octreotide in its depot form is called
Octreotide LAR and can be administered intramuscularly at
a dose of 20 to 30 mg every 4 weeks. Lanreotide is admi-
nistered subcutaneously at a dose of 120 mg every 4 weeks.
The Brazilian Consensus of NETs considers octreotide and
lanreotide to be similarly safe and effective in the antitumor
and symptomatic treatment of well-differentiated gastroen-
teropancreatic NETs (24). In addition, phase III placebo-
controlled trials (62,63) have also demonstrated that these
agents provide antiproliferative effects, prolonging progression-
free survival.
Unfortunately, all patients experience symptomatic pro-
gression of CS after a median of several months to years.
In this scenario, several therapeutic options have been
successfully tested and are discussed below.
Figure 3 - CT showing a characteristic image of mesenteric fibrosis.
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’ REFRACTORY CARCINOID SYNDROME
There is no uniform definition of refractory CS, which
makes it difficult to compare results from different studies.
Most studies consider refractory CS as uncontrolled carci-
noid symptoms despite label doses of somatostatin analo-
gues (64). However, ‘‘uncontrolled’’ is a subjective term.
Except for two randomized trials, the TELESTAR (17) and
the Passport (65), the overwhelming majority of studies pro-
posing treatments for refractory CS are either retrospective or
subgroup analyses of randomized trials. However, despite the
low level of evidence for many therapeutic options to treat
refractory CS, there is consistency in the clinically significant
results for most of them.
Some patients with difficult-to-control diarrhea and flush-
ing may benefit from more frequent doses of octreotide or
lanreotide (66). Some problems may also occur with the
administration of somatostatin analogues, such as decrea-
sed absorption and tachyphylaxis. Related problems due to
decreased absorption by fibrosis from the injection site, for
example, can be avoided through better training of the nurs-
ing staff. However, tachyphylaxis, which causes a shorter
duration of the medication effect, with symptom control for
2 to 3 weeks only, can be reduced by shortening the interval
of drug application, such as every 21 days (67). If disease
control is not achieved after these strategies, it is still possible
to switch to a somatostatin analogue. A phase II study and
case reports have shown short-term improvement in symp-
toms after switching from lanreotide to octreotide or other-
wise, which can be explained by differences in the receptor
affinity of drugs (68).
Telotristat ethyl (17,30) was recently approved by the US
Food and Drug Administration. Together with octreotide,
telotristat reduces the frequency of diarrhea. A prospective
placebo-controlled trial (30) demonstrated that telotristat
significantly reduced diarrhea and urinary levels of 5-HIAA.
The effect of telotristat on facial flushing and CHD needs to
be clarified in further studies. Unfortunately, the Passport
trial, which tested pasireotide for the treatment of refractory
CS, was ineffective in significantly controlling CS when
compared with octreotide LAR 60 mg (65).
An alternative to somatostatin analogues for the treatment
of refractory diarrhea and flushing is interferon alpha, which,
in retrospective studies, has been shown to provide symptom
relief in up to 40-50% patients (69). In addition, the use of
interferon alpha may be associated with some antitumor
effects by stimulating T lymphocytes (70); however, objective
responses are rare (71), and the toxicity profile is unfavorable.
Retrospective studies suggest symptomatic benefit with
the use of everolimus in patients with CS (72). Additionally,
the phase III placebo-controlled trial RADIANT 2 (73) demon-
strated that everolimus combined with octreotide led to more
reduction in the levels of urinary 5-HIAA in comparison with
the levels achieved with octreotide only, although information
about symptomatic response was lacking.
Local liver therapies may be considered for patients with
liver metastases, with the aim of managing the symptoms
of CS and controlling the disease. In the case of potentially
resectable lesions, hepatectomy (74) may be considered, with
long-term disease-free survival in up to 20% patients with
complete resection. When liver lesions are not resectable, the
indication of cytoreductive surgery is more controversial, but
some retrospective studies (75-79) suggest improved pallia-
tion of symptoms. Another effective therapy for refractory
CS is liver transarterial embolization, which can control
carcinoid symptoms in up to 75% of patients (80-82).
Importantly, short-acting octreotide should be adminis-
tered before, during and after the procedure in all these
situations to avoid a carcinoid crisis (24).
Another promising strategy is the use of somatostatin
analogue radiolabeled peptide therapy (PRRT) with lute-
tium177 or yttrium90 to provide radiation directed to the cells
that express somatostatin receptors. Studies suggest signifi-
cant symptom improvement with PRRT (83,84). Prior to
PRRT, it is mandatory to quantify cells with somatostatin
receptors using imaging exams before treatment (octreoscan
or PET-Ga68 DOTATATE). A similar strategy has been used
with meta-iodobenzylguanidine (MIBG), a biogenic amine
that is captured by cells of neural origin and radiolabeled
with iodine. Pathirana et al. (85) showed a positive I-123
MIBG scan test for more than 60% of the patients with well-
differentiated midgut NETs. Small studies suggest symptom
control for refractory patients (85,86).
NETs with CS usually respond poorly to conventional
cytotoxic chemotherapy, and this type of approach is not
recommended (24,87).
The optimal treatment sequence to obtain the best control
of the disease remains unknown. A recent systematic review
conducted by our group (64) proposed a therapeutic sequence
to manage refractory CS, taking into account the type of
progression: only symptomatic or also radiological.
’ CARCINOID HEART DISEASE
The treatment of CHD includes the management of vole-
mia and heart failure, treatment of the NET itself, reduction
in the production of related hormones (with the use of soma-
tostatin analogues), and heart valve repair surgery. The use
of somatostatin analogues, such as octreotide and lanreotide,
improves CS symptoms and reduces urinary levels of 5-HIAA.
However, studies suggest that their use does not lead to
regression of CS or prevent its occurrence (88). Bosentan, an
oral antagonist of the endothelin receptor, has been tested in a
small trial of six patients with CHD and New York Heart
Association (NYHA) functional class III or more, demonstrat-
ing that the right ventricular systolic pressure decreased after
3 and 6 months; the 6-minute walk distance also significantly
improved, and five out of six patients improved their NYHA
functional class (89). More studies are needed to replicate these
encouraging results with bosentan.
Because telotristat ethyl reduces the levels of 5-HIAA in
24-h urine tests, it is may be a promising treatment to prevent
or delay the onset of CHD.
Until now, the treatment that best controls CHD is heart
valve repair surgery; however, it is associated with a high
rate of mortality (perioperative mortality is between 10% and
20% in highly specialized centers) (2). Repair surgery is
indicated only for symptomatic patients who are refractory
to clinical treatment or who have right ventricular dysfunc-
tion (90). However, these are the patients with a higher risk
for unfavorable outcomes.
As for MF, once present, there is no specific treatment to
alleviate the symptoms associated with this CS complication.
However, its development can be prevented by resection of
the primary midgut 5-HT-producing NET, and this is recom-
mended by guidelines (24,87).
CS secondary to well-differentiated NETS has a heteroge-
neous clinical presentation ranging from frustrating symptoms
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such as mild diarrhea and flushing, often misdiagnosed
with menopause symptoms, to symptoms that signifi-
cantly worsen the patient’s quality of life, such as difficult-
to-control diarrhea and fibrotic complications such as MF
and CHD. While it is known that 5-HT plays a central role
in this entity, it is insufficient to justify all the symptoms,
and the pathophysiology of CS is not yet fully understood.
Somatostatin analogues (octreotide and lanreotide) are the
standard treatment for CS and have excellent efficacy. Unfor-
tunately, the disease progresses, and patients experience
carcinoid symptoms that are refractory to label doses to
somatostatin analogue treatment. In this scenario, locoregional
therapies and systemic treatments can be helpful. Telotristat
ethyl, a new drug that inhibits 5-HT synthesis, appears to be a
promising drug for the control of refractory CS.
However, there are many more questions than answers
regarding CS. Therefore, we strongly advocate collaborative
efforts among researchers, institutions and funding agencies
to develop preclinical research to investigate the mechanism
underlying CS, to conduct clinical trials with patients suffer-
ing from CS, to study the prognostic and predictive factors of
current treatments and to generate epidemiological data to
evaluate the real impact of CS.
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